BioQ Pharma and Cipla Enter Into an Agreement to Commercialize BioQ’s Ropivacaine Infusion System in India
Jan 06, 2016
SAN FRANCISCO and MUMBAI, India, Jan. 06, 2016:
BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla Limited, “Cipla,” a global pharmaceutical company that uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.
BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.
Josh Kriesel, President and CEO of BioQ Pharma, remarked, "We are excited to collaborate with Cipla as we expand our worldwide commercial footprint into India. We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals. Cipla's proven, hospital-focused sales and marketing organization will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market, which we believe will benefit from our product’s value-add proposition of increased safety, sterility and convenience."
Nikhil Chopra, Head of Cipla’s India Business, added, "We are very pleased to partner with BioQ Pharma in introducing the Ropivacaine unit-dose infusion system to patients and caregivers in India. We believe that this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain."Dr. Lina Kouatly, Managing Director of Lunatus, noted, "We are thrilled to collaborate with BioQ Pharma as we advance towards introducing two unit-dose infusion pharmaceuticals to the MENA region. BioQ Pharma's innovative infusion pharmaceutical products offer a highly differentiated mode of delivering infusible pharmaceuticals to patients. We see significant utility in BioQ's ready-to-use pharmaceuticals and believe they will remove much of the burden and overhead associated with the time consuming steps normally associated with drug infusions."
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's objective is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's existing commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee’s Pharm, Lunatus and West Pharmaceutical Services.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1,500 plus products across therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems.
Forward Looking Statements (BioQ Pharma Inc.)
This press release may contain forward-looking information about BioQ Pharma Incorporated (the "Company"). Forward-looking statements are statements that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "strong," "upcoming," "prepared" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; and our future performance, as well as the performance of our commercial and manufacturing partners.
All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and some of which are beyond the Company's control that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking information and statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
BioQ Pharma Contact Information:
President and CEO
Chief Financial Officer
Integrated Corporate Relations, Inc (ICR)